Scarica l'app Stockscreener
30.60
1.26%
0.38
Dopo l'orario di chiusura:
30.50
-0.10
-0.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$30.22
Aprire:
$30.59
Volume 24 ore:
879.71K
Relative Volume:
0.43
Capitalizzazione di mercato:
$2.74B
Reddito:
$333.87M
Utile/perdita netta:
$-169.00M
Rapporto P/E:
-15.00
EPS:
-2.04
Flusso di cassa netto:
$-157.30M
1 W Prestazione:
+3.83%
1M Prestazione:
-10.26%
6M Prestazione:
+75.76%
1 anno Prestazione:
+31.90%
Intervallo 1D:
$29.94
$30.99
Intervallo di 1 settimana:
$28.90
$30.99
Portata 52W:
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
Nome
Travere Therapeutics Inc
Settore
Industria
Telefono
888-969-7879
Indirizzo
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
30.60 | 2.70B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-09 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-12-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-20 | Iniziato | Citigroup | Neutral |
| 2023-09-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Ripresa | Evercore ISI | Outperform |
| 2023-07-21 | Iniziato | JP Morgan | Overweight |
| 2023-06-07 | Ripresa | Piper Sandler | Neutral |
| 2023-05-22 | Iniziato | TD Cowen | Outperform |
| 2023-05-05 | Aggiornamento | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-21 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-12-14 | Iniziato | Stifel | Hold |
| 2022-12-05 | Iniziato | Wells Fargo | Overweight |
| 2022-09-21 | Iniziato | Bryan Garnier | Sell |
| 2022-07-14 | Ripresa | Canaccord Genuity | Buy |
| 2022-03-31 | Iniziato | Piper Sandler | Overweight |
| 2022-02-28 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-26 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results - Bluefield Daily Telegraph
Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Travere Therapeutics (TVTX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Travere Therapeutics at Guggenheim Summit: Confident in Strategic Path By Investing.com - Investing.com Canada
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
161,988 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Essex Investment Management Co. LLC - MarketBeat
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Unveiling a 40.86% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Travere Therapeutics, Inc. $TVTX Shares Sold by Federated Hermes Inc. - MarketBeat
Penserra Capital Management LLC Buys Shares of 80,556 Travere Therapeutics, Inc. $TVTX - MarketBeat
Market Review: Is Travere Therapeutics Inc trading at a discountWeekly Trade Analysis & Low Risk Entry Point Guides - baoquankhu1.vn
Piper Sandler Raises Price Target for TVTX to $38.00 | TVTX Stoc - GuruFocus
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CFO Sells 1,745 Shares of Stock - MarketBeat
Technical Reactions to TVTX Trends in Macro Strategies - Stock Traders Daily
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit - Business Wire
Bank of America Securities Sticks to Its Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 100,087 Shares - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $234,797.20 in Stock - MarketBeat
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CFO Sells 7,242 Shares of Stock - MarketBeat
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CAO Sells 4,333 Shares of Stock - MarketBeat
William Rote Sells 12,446 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $230,461.00 in Stock - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative? - Yahoo Finance
Published on: 2026-02-01 07:00:12 - baoquankhu1.vn
Lisanti Capital Growth LLC Invests $3.10 Million in Travere Therapeutics, Inc. $TVTX - MarketBeat
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm - GlobeNewswire
Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think - Seeking Alpha
Hussman Strategic Advisors Inc. Has $1 Million Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm - The Malaysian Reserve
TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Laun - GuruFocus
Travere therapeutics CEO Dube sells $1.8 million in TVTX stock By Investing.com - Investing.com Canada
Travere Therapeutics (NASDAQ:TVTX) CEO Sells $244,131.35 in Stock - MarketBeat
Travere Therapeutics (TVTX) Stock Analysis: Exploring a 40% Upside in Rare Disease Biotechnology - DirectorsTalk Interviews
TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses - GlobeNewswire
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? - AOL.com
Universal Beteiligungs und Servicegesellschaft mbH Boosts Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
BofA remains positive on Travere despite FDA decision delay for Filspari - MSN
Travere Therapeutics provides corporate update and 2026 outlook - MSN
Trading the Move, Not the Narrative: (TVTX) Edition - Stock Traders Daily
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics - intellectia.ai
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook - MSN
Benign Growth For Travere Therapeutics, Inc. (NASDAQ:TVTX) Underpins Stock's 27% Plummet - simplywall.st
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Boston Scientific (BSX) - The Globe and Mail
Emerald Mutual Fund Advisers Trust Buys 59,514 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
How liquid is Travere Therapeutics Inc. stockPortfolio Performance Report & Consistent Profit Trade Alerts - mfd.ru
BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari - Insider Monkey
Travere Therapeutics Inc Azioni (TVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Travere Therapeutics Inc Azioni (TVTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Cline Christopher R. | CHIEF FINANCIAL OFFICER |
Feb 04 '26 |
Sale |
32.19 |
1,745 |
56,168 |
111,226 |
| REED ELIZABETH E | Chief Legal Officer and GC |
Feb 04 '26 |
Sale |
32.18 |
2,994 |
96,359 |
105,211 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):